No Detail Found!

Identification of SET7/9-E2F1 as novel therapeutic biomarkers in hepatocellular carcinoma

Author(s)
Lu Xie The Affiliated Hangzhou Hospital of Nanjing Medical University; Department of Gastroenterology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China; Hangzhou Hospital and Institute of Digestive Diseases, Hangzhou, Zhejiang 310006, P.R. China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, Zhejiang 310006, P.R. China; Department of Cardiology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China.
Ye Gu The Affiliated Hangzhou Hospital of Nanjing Medical University; Department of Gastroenterology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China; Hangzhou Hospital and Institute of Digestive Diseases, Hangzhou, Zhejiang 310006, P.R. China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, Zhejiang 310006, P.R. China.
Qiang Liu The Affiliated Hangzhou Hospital of Nanjing Medical University; Department of Gastroenterology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China; Hangzhou Hospital and Institute of Digestive Diseases, Hangzhou, Zhejiang 310006, P.R. China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, Zhejiang 310006, P.R. China.
Hongzhang Shen The Affiliated Hangzhou Hospital of Nanjing Medical University; Department of Gastroenterology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China; Hangzhou Hospital and Institute of Digestive Diseases, Hangzhou, Zhejiang 310006, P.R. China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, Zhejiang 310006, P.R. China.
Yifeng Zhou The Affiliated Hangzhou Hospital of Nanjing Medical University; Department of Gastroenterology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China; Hangzhou Hospital and Institute of Digestive Diseases, Hangzhou, Zhejiang 310006, P.R. China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, Zhejiang 310006, P.R. China.
Jiangfeng Yang The Affiliated Hangzhou Hospital of Nanjing Medical University; Department of Gastroenterology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China; Hangzhou Hospital and Institute of Digestive Diseases, Hangzhou, Zhejiang 310006, P.R. China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, Zhejiang 310006, P.R. China.
Xiaofeng Zhang The Affiliated Hangzhou Hospital of Nanjing Medical University; Department of Gastroenterology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China; Hangzhou Hospital and Institute of Digestive Diseases, Hangzhou, Zhejiang 310006, P.R. China; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, Zhejiang 310006, P.R. China.
Jinyu Huang The Affiliated Hangzhou Hospital of Nanjing Medical University; Department of Cardiology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China.
Abstract
Our previous studies have shown that SET7/9 promotes hepatocellular carcinoma cells proliferation, invasion and migration via post-translational regulation of E2F1. In this study, we comprehensively analyzed the functions and mechanisms of the SET7/9-E2F1 axis using data mining. Data from the UALCAN database showed abnormal expression of both SET7/9 and E2F1 in multiple cancer types. Survival curves and correlation analysis by GEPIA supported the significant roles of SET7/9 and E2F1 in the progression of HCC. Functional enrichment analysis suggested that the SET7/9-E2F1 axis is involved in the regulation of cell cycle, DNA repair and replication, and gene transcription. Our results implicated the potential of SET7/9 in combination with E2F1 as novel therapeutic targets and prognostic biomarkers in hepatocellular carcinoma.
Publication Details
Page(s) 1553-1563
Published Journal: Pakistan Journal of Zoology, Volume: 55, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
hepatocellular carcinoma, SET7/9, E2F1, pathway
0

Citations

0

Downloads

52

Views